News
Hosted on MSN15d
Senate panel questions Novo Nordisk CEO over decision to discontinue this popular insulinNovo Nordisk's decision has been criticized by some patients with Type 1 diabetes who prefer Levemir over other long-acting "basal" insulins such as Sanofi's Lantus and Novo Nordisk's Tresiba.
The list price of Basaglar will be $316.85 for a pack of five pens, 15% below the list price of Lantus. The companies also hope to steal market share from Novo Nordisk, undercutting the long ...
Novo Nordisk , the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...
Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results